Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/7828
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMeikle, P.en
dc.contributor.authorRanieri, E.en
dc.contributor.authorSimonsen, H.en
dc.contributor.authorRozaklis, T.en
dc.contributor.authorRamsay, S.en
dc.contributor.authorWhitfield, P.en
dc.contributor.authorFuller, M.en
dc.contributor.authorChristensen, E.en
dc.contributor.authorSkovby, F.en
dc.contributor.authorHopwood, J.en
dc.date.issued2004en
dc.identifier.citationPediatrics, 2004; 114(4):909-916en
dc.identifier.issn0031-4005en
dc.identifier.issn0031-4005en
dc.identifier.urihttp://hdl.handle.net/2440/7828-
dc.description.abstractOBJECTIVE: To evaluate the use of protein markers using immune-quantification assays and of metabolite markers using tandem mass spectrometry for the identification, at birth, of individuals who have a lysosomal storage disorder. METHODS: A retrospective analysis was conducted of Guthrie cards that were collected from newborns in Denmark during the period 1982-1997. Patients whose lysosomal storage disorder (LSD; 47 representing 12 disorders) was diagnosed in Denmark during the period 1982-1997 were selected, and their Guthrie cards were retrieved from storage. Control cards (227) were retrieved from the same period. Additional control cards (273) were collected from the South Australian Screening Centre (Australia). RESULTS: From 2 protein and 94 metabolite markers, 15 were selected and evaluated for their use in the identification of LSDs. Glycosphingolipid and oligosaccharide markers showed 100% sensitivity and specificity for the identification of Fabry disease, alpha-mannosidosis, mucopolysaccharidosis (MPS) IVA, MPS IIIA, Tay-Sachs disease, and I-cell disease. Lower sensitivities were observed for Gaucher disease and sialidosis. No useful markers were identified for Krabbe disease, MPS II, Pompe disease, and Sandhoff disease. The protein markers LAMP-1 and saposin C were not able to differentiate individuals who had an LSD from the control population. CONCLUSIONS: Newborn screening for selected LSDs is possible with current technology. However, additional development is required to provide a broad coverage of disorders in a single, viable program.en
dc.description.statementofresponsibilityPeter J. Meikle, Enzo Ranieri, Henrik Simonsen, Tina Rozaklis, Steve L. Ramsay, Phillip D. Whitfield, Maria Fuller, Ernst Christensen, Flemming Skovby, John J. Hopwooden
dc.language.isoenen
dc.publisherAmer Acad Pediatricsen
dc.rightsCopyright © 2004 by the American Academy of Pediatricsen
dc.subjectgenetic disease; mass spectrometry; oligosaccharide; glycolipid; protein markeren
dc.titleNewborn screening for lysosomal storage disorders: Clinical evaluation of a two-tier strategyen
dc.typeJournal articleen
dc.identifier.rmid0020040984en
dc.identifier.doi10.1542/peds.2004-0583en
dc.identifier.pubid56634-
pubs.library.collectionPaediatrics publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
Appears in Collections:Paediatrics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.